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with Parkinson's diseaseDear Editor,
Parkinson's disease is derived from a degeneration of the dopa-
minergic neurons in the substantia nigra pars compacta, which
leads to a marked loss of striatal dopamine concentration. Among
the treatment for Parkinson's disease, the number of patients tak-
ing dopamine D2 receptor agonist is on the rise. Ropinirole, a selec-
tive dopamine D2 receptor agonist, shows a strong inhibitory effect
on the pathogenesis of Parkinson's disease.1 Although several
adverse events of ropinirole are well-known, such as sleep distur-
bance, a drug eruption due to ropinirole has not been reported in
English so far. Herein, we describe here an unusual case of a patient
with Parkinson's disease who developed multiple ﬁxed drug erup-
tion after ropinirole treatment. We also reviewed the past
literature on drug eruption caused by other dopamine D2 receptor
agonists further.
A 60-year-old female with Parkinson's disease was referred to
our department for evaluation of an eruption of 2 days' duration.
An erythematous eruption on the extremities had developed three
hours after 7th daily administration of ropinirole for her Parkin-
son's disease. The erythematous lesions gradually became pig-
mented. On physical examination, well-deﬁned pigmentations
surrounded by erythema were observed on the right arm
(Fig. 1A). Laboratory and biochemical proﬁles were within normal
ranges. At the ﬁrst visit, a skin biopsy specimen taken from an
erythematous lesion on the right arm revealed a lymphocytic inﬁl-
trate in the epidermis and upper dermis (Fig. 1B). From clinical
course and skin biopsy ﬁndings, we guessed her skin eruption as
drug eruption. Two weeks after the ﬁrst visit, patch testing with
the concentration of 10 and 20% ropinirole using vaseline vehicle
(White Petrolatum®, Kenei Pharmaceutical, Osaka, Japan) on the
pigmented macule was negative.
At the ﬁrst visit, we performed lymphocyte stimulation test
(LST) with ropinirole as described previously.2 3H-thymidine incor-
porationwas signiﬁcantly increased by the addition of 4.3 108 M
ropinirole (corresponding to Cmax) to the peripheral lymphocyte
culture with stimulation index of 2.1 (Fig. 1C). Although she had
other medications, LST and patch test were negative results. Based
on the clinical course and laboratory examination, we diagnosed
the rash as multiple ﬁxed drug eruption due to ropinirole. After
discontinuation of ropinirole, her eruption improved remarkably
in a week, with residual pigmentation.
Although several case reports have already been published on
other dopamine D2 receptor agonists, to our knowledge, this isPeer review under responsibility of Japanese Society of Allergology.
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eruption, caused by ropinirole. We reviewed the English reported
cases of drug eruption caused by pure dopamine D2 receptor
agonist (Table 1).3e6 There have been 9 reported cases including
our case. Seven cases were due to bromocriptine, and the major
clinical manifestation is erythromelalgia. In the past literature,
the details of identiﬁcation of causative drugs remained obscure.
In our patient, the apparently positive LST with ropinirole
conﬁrmed the causative drug. As shown in our previous report, pa-
tients with multiple ﬁxed drug eruption tend to show positive re-
sults in LST.2 The exact pathomechanism remains unclear,
however, circulating T cells might play some roles in the pathogen-
esis of multiple ﬁxed drug eruption. Because the molecular weight
of ropinirole is 296.84, ropinirole can penetrate under basal layer of
epidermis. However, we used vaseline vehicle in the patch test,
while ropinirole is a water-soluble drug. In view of this chemical
nature, vaseline vehicle might be not suitable for the patch test
using ropinirole. Likewise, Wiesli P, et al. reported case in which,
the result of patch test was also negative,5 even though the type
of eruption was different from our case. Although they did not
specify a vehicle in their case report, they might also use vaseline
vehicle in patch test. Therefore, the result of patch test in our
case might be false-negative due to usage of inappropriate solvent.
The patient declined to undertake another patch test with ropinir-
ole solved in aqueous material. Although, it has been known that
dopamine D2 receptor agonist has an inhibitory effect of T cell acti-
vation,7 LST might help us to identify the causative drug of dopa-
mine D2 receptor agonist. It is necessary to keep in mind that the
incidence might be a relatively rare but ropinirole has a risk of
causing cutaneous adverse events.
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Fig. 1. (A) Physical examination revealed multiple erythematous pigmented macules
of various sizes on a right arm. (B) Histological examination showing a lymphocytic
inﬁltrate in the epidermis and upper dermis. (C) Lymphocyte stimulation index (SI).
The patient's peripheral blood mononuclear cells (3  105/well) taken at the initial visit
were cultured for 72 h in a 96-well plate with ropinirole at 4.3  108 M (correspond-
ing to Cmax). Results are presented as the mean ± SEM. P-value was obtained by stu-
dent's t-test. *P < 0.05.
Table 1
Case report of drug eruption caused by pure dopamine D2 receptor agonist.
Author Age/Sex Drug Eruption type To identify
causative drug
Kaushik et al.3 25/Female Cabergoline Erythema
nodosum
Challenge test:
positive
Leshin et al.4 57/Male Bromocriptine Morphea N.D
Wiesli et al.5 28/Female Bromocriptine Pseudolymphoma Patch test &
scratch test:
negative
Eisler et al.6 N.D Bromocriptine Erythromelalgia N.D
N.D Bromocriptine Erythromelalgia N.D
N.D Bromocriptine Erythromelalgia N.D
N.D Bromocriptine Erythromelalgia N.D
N.D Bromocriptine Erythromelalgia N.D
Our case 60/Female Ropinirole Fixed drug
eruption
LST: positive
Patch test:
negative
N.D, not described.
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